bgb-a425
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 27, 2018 (NCT03744468)
Timeline
Indications
Mechanism of action
HAVCR2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05909904 | Phase 2 | Jul 21, 2023 | BeOne Medicines |
| NCT03744468 | Phase 1/Phase 2 (Phase 2) | Aug 27, 2018 | BeOne Medicines |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BeOne Medicines | For profit | 2 | 2 | 1 | 2018 |
1 organizations
Page 1 / 1